4YD.F Stock Analysis
4Y
Uncovered
Nanologica AB (publ) is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Nanologica AB engages in the research and development of pharmaceutical products. The company is headquartered in Sodertalje, Stockholm. The company went IPO on 2015-10-30. The firm specializes in developing nanoporous materials from nanoporous silica (silicon dioxide) for a variety of applications, ranging from purification to pharmaceutical excipients. The firm's core competency has been developed and expanded in two areas of application, in particular: Drug Delivery and Chromatography, a technology used for the separation and purification of products on the market and in development. The firm's Drug Delivery sector operates within a niche domain of nanocarriers. Nanologica AB (publ)’s drug delivery technology is aimed on absorption of the medicine by the body for drugs that are poorly soluble in water.